Less necessity of adjuvant S-1 treatment in non-monarchE-eligible patients.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6006
Abstract: BACKGROUND In monarchE and Postoperative Therapy with Endocrine and TS-1 (POTENT) trials, abemaciclib and S-1 have, respectively, shown to be effective as adjuvant therapies for luminal breast cancer (BC), although whether patients who meet the… read more here.
Keywords: eligible patients; potent; monarche eligible; non eligible ... See more keywords
Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care.
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2019.240762
Abstract: Infections cause significant morbidity and mortality in myeloma, contributing to up to 50% of early deaths. The increased risk is attributed to immunoparesis and immunosuppressive therapy. The nature and patterns of infections evolved over time,… read more here.
Keywords: morbidity; myeloma; newly diagnosed; infection ... See more keywords